Ranbaxy not a stock for investment portfolio: Ambareesh Baliga
PUBLISHED ON: January 24, 2014 | Duration: 11 min, 50 sec
Ranbaxy is a traders' stock, Ambareesh Baliga of Edelweiss Global Wealth told NDTV after shares in the company crashed 20 per cent on US FDA ban on its Toansa plant. The stock can never be a "buy" looking at the adverse news flow over the last 18 months, he added.
